Patient-reported symptoms are a more reliable predictor of the societal burden compared to established physician-reported activity indices in inflammatory bowel disease: a cross-sectional study

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770.
   PubMed Web of Science ®Google Scholar
• Torres J, Mehandru S, Colombel J-F, et al. Crohn’s disease. Lancet Lond Engl. 2017;389(10080):1741–1755.
   PubMed Web of Science ®Google Scholar
• Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. PharmacoEconomics. 2014;32(4):335–344.
   PubMed Web of Science ®Google Scholar
• Kawalec P. Indirect costs of inflammatory bowel diseases: crohn’s disease and ulcerative colitis. A systematic review. Arch Med Sci AMS. 2016;2:295–302.
   Google Scholar
• Constantin J, Atanasov P, Wirth D, et al. Indirect costs associated with ulcerative colitis: a systematic literature review of real-world data. BMC Gastroenterol. 2019;19(1):179.
   PubMed Web of Science ®Google Scholar
• Sturm A, Maaser C, Calabrese E, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 2: IBD scores and general principles and technical aspects. J Crohns Colitis. 2019;13:273–284.
   PubMed Web of Science ®Google Scholar
• Mentella MC, Scaldaferri F, Pizzoferrato M, et al. The association of disease activity, BMI and phase angle with vitamin D deficiency in patients with IBD. Nutrients. [Internet]. Multidisciplinary Digital Publishing Institute; 2019 cited 2022 Oct 18;11(11):2583.
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4(5):353–365.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–349.
   PubMed Web of Science ®Google Scholar
• Yarlas A, Maher SM, Bayliss MS, et al. Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review. J Patient-Rep Outcomes. 2018;2(1):62.
   PubMedGoogle Scholar
• Yarlas A, D’Haens G, Willian MK, et al. Health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis and remission status following short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study. Inflamm Bowel Dis. Internet]. 2018 cited 2022 Feb 26;24(2):450–463.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Peyrin-Biroulet L, Sturm A, et al. Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - multicenter European cohort study. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2016;48:592–600.
   Google Scholar
• Vaizey CJ, Gibson PR, Black CM, et al. Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: an observational study. Frontline Gastroenterol. 2014;5(3):183–189.
   PubMedGoogle Scholar
• Michael MD, Bálint A, Lovász BD, et al. Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. Eur J Health Econ. 2014. Internet]. cited 2021 Jun 29;15(S1):121–128.
   Web of Science ®Google Scholar
• Gibson PR, Vaizey C, Black CM, et al. Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study. J Crohns Colitis. 2014;8(7):598–606.
   PubMed Web of Science ®Google Scholar
• [email protected] Ac-. Pension Insurance Act No. 306/2008 Coll. § 39 [Internet]. cited 2022 Apr 20]. 2022 Apr 20 Zák. Lidi Available from. https://www.zakonyprolidi.cz/cs/2008-306
   Google Scholar
• Disability - ČSSZ Web EN - Česká správa sociálního zabezpečení [Internet]. cited 2022 Apr 20]. Available from 2022 Apr 20: https://www.cssz.cz/web/en/disability
   Google Scholar
• van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. Internet]. BMJ Publishing Group Ltd; 2010 cited 2022 Apr 20;69(Suppl 1):i89–91.
   PubMedGoogle Scholar
• Zhang W, Bansback N, Anis AH. Measuring and valuing productivity loss due to poor health: a critical review. Soc Sci Med. Internet]. 2011 cited 2021 Jun 28;72(2):185–192.
   PubMed Web of Science ®Google Scholar
• Tužil J, Mlčoch T, Jirčíková J, et al. Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry. Expert Opin Biol Ther. 2020;20(2):183–192.
   PubMed Web of Science ®Google Scholar
• Holko P, Kawalec P, Mossakowska M, et al. Health-Related Quality of Life Impairment and Indirect Cost of Crohn’s Disease: a Self-Report Study in Poland. PLOS ONE. Internet]. Public Library of Science; 2016 cited 2022 Apr 19;11(12):e0168586.
   PubMed Web of Science ®Google Scholar
• Bernklev T, Jahnsen J, Henriksen M, et al. Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(5):402–412.
   PubMed Web of Science ®Google Scholar
• Knies S, Candel MJJM, Boonen A, et al. Lost productivity in four European Countries among patients with rheumatic disorders. PharmacoEconomics. 2012;30(9):795–807.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Bala M, et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13(9):1135–1140.
   PubMed Web of Science ®Google Scholar
• Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol. 1997;32(11):1134–1139.
   PubMed Web of Science ®Google Scholar
• Mesterton J, Jönsson L, Almer SHC, et al. Resource use and societal costs for Crohn’s disease in Sweden. Inflamm Bowel Dis. 2009;15:(12)1882–1890.
   PubMed Web of Science ®Google Scholar
• Benedini V, Caporaso N, Corazza GR, et al. Burden of Crohn’s disease: economics and quality of life aspects in Italy. Clin Outcomes Res CEOR. 2012;4(12):209–218.
   PubMedGoogle Scholar
• Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004;53(10):1471–1478.
   PubMed Web of Science ®Google Scholar
• Juan J, Estiarte R, Colomé E, et al. Burden of illness of Crohn’s disease in Spain. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2003;35:853–861.
   Google Scholar
• Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the national health interview survey. Am J Gastroenterol. 2003;98(5):1064–1072.
   PubMed Web of Science ®Google Scholar
• Longobardi T, Jacobs P, Wu L, et al. Work losses related to inflammatory bowel disease in Canada: results from a national population health Survey. Am J Gastroenterol. 2003;98(4):844–849.
   PubMed Web of Science ®Google Scholar
• Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol. 1992;14(4):309–317.
   PubMed Web of Science ®Google Scholar
• Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn’s disease and ulcerative colitis. J Occup Environ Med. 2008;50(11):1261–1272.
   PubMed Web of Science ®Google Scholar
• Stark R, König -H-H, Leidl R. Costs of inflammatory bowel disease in Germany. PharmacoEconomics. 2006;24(8):797–814.
   PubMed Web of Science ®Google Scholar
• Kuenzig ME, Lee L, El-Matary W, et al. The Impact of Inflammatory Bowel Disease in Canada 2018: indirect Costs of IBD Care. J Can Assoc Gastroenterol. 2019;2(Supplement_1):S34–41.
   PubMedGoogle Scholar
• Walter E, Hausberger S-C, Groß E, et al. Health-related quality of life, work productivity and costs related to patients with inflammatory bowel disease in Austria. J Med Econ. 2020;23(10):1061–1071.
   PubMed Web of Science ®Google Scholar
• Ruiz-Casas L, Evans J, Rose A, et al. The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe. BMC Gastroenterol. 2021;21(1):456.
   PubMed Web of Science ®Google Scholar
• Alatab S, Sepanlou SG, Ikuta K, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol [Internet]. Elsevier. 2020 cited 2021 Jun 27;5:17–30.
   Web of Science ®Google Scholar
• Cox E, Martin BC, Van Staa T, et al. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report–Part II. Value Health J Int Soc PharmacoEcon Outcomes Res. 2009;12:1053–1061.
   Google Scholar
• Johnson ML, Crown W, Martin BC, et al. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report–Part III. Value Health J Int Soc PharmacoEcon Outcomes Res. 2009;12:1062–1073.
   Google Scholar